Glyten Tablet contains Teneligliptin 20 mg, a potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for the management of type 2 diabetes mellitus. Teneligliptin enhances the incretin system by inhibiting the DPP-4 enzyme, thereby increasing the levels of active incretin hormones such as GLP-1 and GIP. These hormones stimulate insulin secretion in a glucose-dependent manner and suppress glucagon release, leading to improved glycemic control without causing significant hypoglycemia. Glyten Tablet is prescribed as an adjunct to diet and exercise to improve glycemic parameters in adults with inadequate control on monotherapy or combination therapy. The recommended dosage is 20 mg once daily, with or without food. Teneligliptin exhibits a favorable pharmacokinetic profile, including a long half-life that supports once-daily dosing and minimal renal clearance, making it suitable for patients with varying degrees of renal impairment without dose adjustment. Adverse effects are generally mild and may include nasopharyngitis, headache, or gastrointestinal discomfort. Glyten Tablet should be used cautiously in patients with a history of pancreatitis. Regular monitoring of blood glucose levels and renal function is advised during therapy to ensure optimal efficacy and safety.